,0
symbol,ARVN
price,23.27
beta,0.0
volAvg,412915
mktCap,943575230
lastDiv,0.0
range,19.68-61.57
changes,-0.22
companyName,Arvinas Inc
currency,USD
cik,0001655759
isin,US04335A1051
cusip,04335A105
exchange,NasdaqGS
exchangeShortName,NASDAQ
industry,Biotechnology
website,http://arvinas.com/
description,"Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. The company is headquartered in New Haven, Connecticut and currently employs 103 full-time employees. The firm is engaged in the development and commercialization of therapies to degrade disease-causing proteins. The firm uses its technology platform to engineer proteolysis targeting chimeras (PROTACs), which are designed to harness the bodyâ€™s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. The firm is using its PROTAC platform to build an pipeline of protein degradation product candidates to target diseases in a wide range of organ systems and tissues. The company is also focused on advancing its lead product candidates, ARV-110 and ARV-471, into Phase 1 clinical trials. The company seeks to initiate a Phase 1 clinical trial for ARV-110 in men with metastatic castration-resistant prostate cancer (mCRPC), and a Phase 1 clinical trial for ARV-471 in women with metastatic ER positive, HER2 negative breast cancer, or ER+ breast cancer."
ceo,Dr. John Houston
sector,Healthcare
country,US
fullTimeEmployees,133
phone,12035351456
address,5 Science Park
city,New Haven
state,CONNECTICUT
zip,06511
dcfDiff,
dcf,20.4697
image,https://financialmodelingprep.com/image-stock/ARVN.png
ipoDate,2018-09-27
defaultImage,False
